skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Discovery of selective inhibitors of tyrosyl-DNA phosphodiesterase 2 by targeting the enzyme DNA-binding cleft

Authors:
; ; ; ; ; ; ;
Publication Date:
Sponsoring Org.:
USDOE
OSTI Identifier:
1328580
Grant/Contract Number:
AC02-05CH11231
Resource Type:
Journal Article: Publisher's Accepted Manuscript
Journal Name:
Bioorganic and Medicinal Chemistry Letters
Additional Journal Information:
Journal Volume: 26; Journal Issue: 14; Related Information: CHORUS Timestamp: 2017-10-07 03:34:41; Journal ID: ISSN 0960-894X
Publisher:
Elsevier
Country of Publication:
United Kingdom
Language:
English

Citation Formats

Kossmann, Bradley R., Abdelmalak, Monica, Lopez, Sophia, Tender, Gabrielle, Yan, Chunli, Pommier, Yves, Marchand, Christophe, and Ivanov, Ivaylo. Discovery of selective inhibitors of tyrosyl-DNA phosphodiesterase 2 by targeting the enzyme DNA-binding cleft. United Kingdom: N. p., 2016. Web. doi:10.1016/j.bmcl.2016.05.065.
Kossmann, Bradley R., Abdelmalak, Monica, Lopez, Sophia, Tender, Gabrielle, Yan, Chunli, Pommier, Yves, Marchand, Christophe, & Ivanov, Ivaylo. Discovery of selective inhibitors of tyrosyl-DNA phosphodiesterase 2 by targeting the enzyme DNA-binding cleft. United Kingdom. doi:10.1016/j.bmcl.2016.05.065.
Kossmann, Bradley R., Abdelmalak, Monica, Lopez, Sophia, Tender, Gabrielle, Yan, Chunli, Pommier, Yves, Marchand, Christophe, and Ivanov, Ivaylo. 2016. "Discovery of selective inhibitors of tyrosyl-DNA phosphodiesterase 2 by targeting the enzyme DNA-binding cleft". United Kingdom. doi:10.1016/j.bmcl.2016.05.065.
@article{osti_1328580,
title = {Discovery of selective inhibitors of tyrosyl-DNA phosphodiesterase 2 by targeting the enzyme DNA-binding cleft},
author = {Kossmann, Bradley R. and Abdelmalak, Monica and Lopez, Sophia and Tender, Gabrielle and Yan, Chunli and Pommier, Yves and Marchand, Christophe and Ivanov, Ivaylo},
abstractNote = {},
doi = {10.1016/j.bmcl.2016.05.065},
journal = {Bioorganic and Medicinal Chemistry Letters},
number = 14,
volume = 26,
place = {United Kingdom},
year = 2016,
month = 7
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record at 10.1016/j.bmcl.2016.05.065

Citation Metrics:
Cited by: 1work
Citation information provided by
Web of Science

Save / Share:
  • PDE9 inhibitors have been studied as therapeutics for treatment of cardiovascular diseases, diabetes, and neurodegenerative disorders. To illustrate the inhibitor selectivity, the crystal structures of the PDE9A catalytic domain in complex with the enantiomers of PDE9 inhibitor 1-(2-chlorophenyl)-6-(3,3,3-trifluoro-2-methylpropyl)-1H-pyrazolo[3,4-d]pyrimidine-4(5H)-one ((R)-BAY73-6691 or (S)-BAY73-6691, 1r or 1s) were determined and mutagenesis was performed. The structures showed that the fluoromethyl groups of 1r and 1s had different orientations while the other parts of the inhibitors commonly interacted with PDE9A. These differences may explain the slightly different affinity of 1r (IC{sub 50} = 22 nM) and 1s (IC{sub 50} = 88 nM). The mutagenesis experimentsmore » revealed that contribution of the binding residues to the inhibitor sensitivity varies dramatically, from few-fold to 3 orders of magnitude. On the basis of the crystal structures, a hypothesized compound that simulates the recently published PDE9 inhibitors was modeled to provide insight into the inhibitor selectivity.« less
  • A number of novel amidine containing heterocycles were designed to reproduce the unique interaction pattern, revealed by X-ray crystallography, between the BACE-1 catalytic diad and a weak NMR screening hit (3), with special attention paid to maintaining the appropriate basicity and limiting the number of H-bonding donors of these scaffolds. The iminohydantoin cores (10 and 23) were examined first and found to interact with the catalytic diad in one of two binding modes (A and B), each with the iminohydantoin core flipped 180º in relation to the other. The amidine structural motif within each core forms a bidentate interaction withmore » a different aspartic acid of the catalytic diad. Both modes reproduced a highly conserved interaction pattern between the inhibitors and the catalytic aspartates, as revealed by 3. Potent iminohydantoin BACE-1 inhibitors have been obtained, validating the molecular design as aspartyl protease catalytic site inhibitors. Brain penetrant small molecule BACE inhibitors with high ligand efficiencies have been discovered, enabling multiple strategies for further development of these inhibitors into highly potent, selective and in vivo efficacious BACE inhibitors.« less
  • A number of novel amidine containing heterocycles were designed to reproduce the unique interaction pattern, revealed by X-ray crystallography, between the BACE-1 catalytic diad and a weak NMR screening hit, with special attention paid to maintaining the appropriate basicity and limiting the number of H-bonding donors of these scaffolds. The iminohydantoin cores were examined first and found to interact with the catalytic diad in one of two binding modes (A and B), each with the iminohydantoin core flipped 180° in relation to the other. The amidine structural motif within each core forms a bidentate interaction with a different aspartic acidmore » of the catalytic diad. Both modes reproduced a highly conserved interaction pattern between the inhibitors and the catalytic aspartates. Potent iminohydantoin BACE-1 inhibitors have been obtained, validating the molecular design as aspartyl protease catalytic site inhibitors. Brain penetrant small molecule BACE inhibitors with high ligand efficiencies have been discovered, enabling multiple strategies for further development of these inhibitors into highly potent, selective and in vivo efficacious BACE inhibitors.« less